BTIG Starts Perspective Therapeutics Inc (CATX) at Buy, PT $14

BTIG analyst Jeet Mukherjee initiates coverage on Perspective Therapeutics Inc (NYSE: CATX) with a Buy rating and a price target of $14.00.

The analyst comments "We see Perspective as a leader in the next-gen radiopharmaceutical space, having proprietary know-how in developing potent lead-212 isotope based therapies that could provide greater efficacy and cleaner safety vs. first gen radiopharma agents. At $289M in mkt cap, we see room for shares to appreciate headed into key catalysts at ESMO and into 2026 across key programs. While the radiopharmaceutical space is increasingly competitive, Perspective's investment in a US regional manufacturing network coupled with deep technical expertise in lead based radiopharmaceuticals provides high barriers to entry and scarcity value in its platform which should remain of long-term interest to pharma strategics."

For an analyst ratings summary and ratings history on Perspective Therapeutics Inc click here. For more ratings news on Perspective Therapeutics Inc click here.

Shares of Perspective Therapeutics Inc closed at $3.86 yesterday.

You May Also Be Interested In

• Stripe, Advent In Talks To Buy Paypal - WSJ
• Perspective Therapeutics Inc (CATX) PT Lowered to $5 at BofA Securities
• Cantor Fitzgerald Reiterates Overweight Rating on Applied Materials (AMAT)